.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Chubb
Julphar
Mallinckrodt
Cerilliant
Baxter
Cantor Fitzgerald
Novartis
US Army

Generated: September 24, 2017

DrugPatentWatch Database Preview

OFIRMEV Drug Profile

« Back to Dashboard

Which patents cover Ofirmev, and when can generic versions of Ofirmev launch?

Ofirmev is a drug marketed by Mallinckrodt Ip and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-six countries.

The generic ingredient in OFIRMEV is acetaminophen. There are sixty-six drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.

Summary for Tradename: OFIRMEV

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list99
Clinical Trials: see list41
Patent Applications: see list9,597
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OFIRMEV at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► Subscribe ► Subscribe
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► SubscribeY► Subscribe
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► SubscribeY► Subscribe
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► SubscribeY► Subscribe
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► Subscribe► Subscribe
Mallinckrodt Ip
OFIRMEV
acetaminophen
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OFIRMEV

Drugname Dosage Strength RLD Submissiondate
acetaminophenInjection1000 mg/100 mL (10 mg/mL)Ofirmev4/7/2011

International Patent Family for Tradename: OFIRMEV

Country Document Number Estimated Expiration
New Zealand523458► Subscribe
JapanH11514013► Subscribe
Japan5909750► Subscribe
Poland326069► Subscribe
China1556694► Subscribe
World Intellectual Property Organization (WIPO)2009064928► Subscribe
Portugal858329► Subscribe
Russian Federation2192249► Subscribe
TaiwanI237570► Subscribe
Peru05082003► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Moodys
Fuji
McKesson
McKinsey
Medtronic
Cerilliant
Accenture
Argus Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot